Antiviral Drugs Market

Global Antiviral Drugs Market Size (2024 to 2032)

The global antiviral drugs market was valued at USD 37.48 billion in 2023. The global antiviral drugs market is predicted to grow to USD 58.90 billion by 2032 from USD 39.41 billion in 2024. This market is forecasted to grow at a CAGR of 5.15% during the forecast period.

Current Scenario of the Global Antiviral Drugs Market

Antiviral drugs are described as curative or disease-controlling agents against viral infections. These drugs individually attack viruses at different metabolic processes and alter the normal functioning of viral particles. However, over the past few years, resistance has been observed among viruses against different antiviral drugs with an increasing diversity of microorganisms. This challenge led to the evolution of broad-spectrum antiviral medicines that attack viruses at specified targets, such as DNA Polymerase, NS3 Protease, & Reverse Transcriptase. These drugs prevent or cure viral infections such as HIV/AIDS, Hepatitis, influenza, and other infections.

Anti-virus drugs are a class of medicine that kills a virus such as HIV, chickenpox, papilloma, hepatitis B and C viruses, herpes viruses, influenza A and b viruses, or suppress the virus's ability to replicate. Most anti-viruses target specific types of viruses. Moreover, a broad-spectrum anti-virus drug is effective against an extensive range of viruses. On the other hand, the unlanti-viral number of antibiotics and antiviral drugs do not kill their target pathogen. The global antiviral drug market showed consistent growth in the pharmaceutical industry and is predicted to continue the growing trend in the coming years due to the rise in awareness in the people and better efficiency of the developed drug. The significant patents in anti-virus drugs are Tenofovir, Tamiflu, Relenza, Telbivudine, and Sustivahave changed the anti-virus face.

MARKET DRIVERS

Y-O-Y's growth in the incidence of viral infections is majorly accelerating the growth of the global antiviral drugs market.

The global antiviral drugs market is primarily driven by infections such as influenza, respiratory syncytial virus, hepatitis, and HIV. An increase in research and development activities and innovation of new formulations, including vaccines and various therapy, is anticipated to drive the market's growth. According to the report of UNAIDS, there were 37.9 million people globally who had HIV/AIDS in 2019. Of that, 36.2 million people were adults, 1.7 million were children, and 770000 died from this disease.

Additionally, growing public awareness, a boost in the R &D segment, increasing interest to support the development of novel antiviral drugs, and a well-established supply chain further lavish the growth of the global antiviral drugs market.

Furthermore, the rise in healthcare infrastructure spending capability in developed and developing countries, increasing dilation of life-threatening virus disease, and people awareness fuel market growth. As late-stage pipeline drugs are anticipated to hit the market, this further supports the antiviral drugs market growth.

MARKET RESTRAINTS

The high cost involved in developing drugs and increased demand for different medicine like naturopathy and homeopathy-viral is degrading the market growth of antiviral medication. In addition to this high risk of failure, the high cost of research and therapy and stringent government activities hamper the market's growth. Therefore, increasing the use of natural products is the market's critical challenge.

Furthermore, increasing preventive measures and the availability of vaccines for various viral diseases hamper the antiviral drugs market growth to some extent.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Antiviral Drugs Market By Application

Based on application, the HIV/AIDS and the Hepatitis segments accounted for the highest market share in the global antiviral drugs market in 2023 and are predicted to continue their domination throughout the forecast period. The growth is primarily driven due to the standard increase of transmitted infectious diseases.

Global Antiviral Drugs Market By Target

Based on the target, the reverse transcriptase segment is projected to perform well during the forecast period. Therefore, this segment will influence the antiviral drugs market in the forthcoming years due to its efficacy in averting or slowing down viral infections.

Global Antiviral Drugs Market By End Users

Based on the End-User, the hospital's segment was accounted for the largest share in 2023 and forecasted to grow at the highest CAGR during the forecast period. The segment's growth is attributed to many patients and their admissions, which are responsible for the growth of the antiviral drugs market.

Global Antiviral Drugs Market By Region

Regionally, the North American antiviral drugs market is forecasted to be the most influencing region in the global antiviral drugs market and will account for more than 34.0% of the global market share in 2023. The factors responsible for the market's growth in this region include an emergency of the critical situation of diseases and a standard increase of infectious diseases across the globe. In this region, the United States is the leading market.

The Europe market stands second in leading highest shares in the global antiviral drugs market, followed by North America. The European antiviral drugs market size is projected to grow at a CAGR value of 4.98% over the forecast period. Factors such as new vaccines coming into the market by the key players and common infectious diseases fuel market growth. The UK leads the market in this region.

The Asia-Pacific market is expected to grow fast, with a CAGR value of 6.12% from 2024 to 2029. China is the most lucrative country in the Asia Pacific antiviral drugs market, obtaining majority shares in the market in 2023 due to increasing knowledge in public and the launch of new products. Japan is next to China in showcasing a healthy CAGR.

The Latin American antiviral drugs market size is estimated to be worth USD 5.06 billion by 2029. In addition, the governments of the Latin America region are working on introducing new antiviral drugs for those who are suffering from infectious diseases like Hepatitis C, also HIV/AIDS. These factors are responsible for market growth in Latin America.

The Middle East & Africa region is estimated to showcase a CAGR of 5.07% during the forecast period. Factors such as increased healthcare expenditure, rising occurrence of viral infections, and utilization of natural medicines are majorly propelling the market growth in this region.

KEY MARKET PARTICIPANTS

Companies leading the global antiviral drugs market profiled in this report are Johnson & Johnson (USA), Novartis International AG (Switzerland), Roche Holding AG (Switzerland), Pfizer (USA), Merck and Co. Inc. (USA), GlaxoSmithKline plc (United Kingdom), AstraZeneca AB (United Kingdom), Gilead Sciences (USA) and Abbott Laboratories (USA).

DETAILED SEGMENTATION OF THE GLOBAL ANTIVIRAL DRUGS MARKET INCLUDED IN THIS REPORT

This research report on the global antiviral drugs market is segmented and sub-segmented based on the application, target, end-users, and region.

By Application

• HIV/AIDS
• Hepatitis
• Herpes
• Influenza

By Target

• DNA Polymerase
• NS3 Protease
• Reverse Transcriptase

By End Users

• Hospitals
• Research Institutes
• Laboratory Centers

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa